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A b s t r a c t  
The aim of the present study was to formulate and evaluate the transdermal patches of an 
antipsychotic drug Quetiapine fumerate (QF) for the treatment of psychosis and schizophrenia. The 
transdermal patches was prepared by the solvent evaporation method using hydroxy propyl methyl 
cellulose (HPMC) and ethyl cellulose (EC) in five different ratios 1:0, 2:1, 1:1, 1:2, 0:1. The PEG-400 
and DMSO were used as plasticizers and permeation enhancer respectively to enhance the 
permeability of the drug. The FTIR studies showed no evidence of incompatibility between the drug 
and the polymers. The prepared patches were evaluated for various parameters like thickness, 
weight variation, folding endurance, percentage moisture uptake, percentage moisture content, drug 
content and in-vitro drug release. The results concluded that the formulation F2 (with HPMC and EC 
in 2:1 ratio) showed 80.89% in drug release during in-vitro studies after 24 hours. With the 
incorporation of PEG-400 and DMSO smooth, transparent and flexible film were produced. 
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Introduction 
During the past two decades, significant advances have been 
made in the area of controlled release as evidenced by an 
increasing number of patents, publications, as well as commercial 
controlled-release products for the delivery of a variety of bioactive 
agents ranging from pharmaceutical to agricultural and veterinary 
compounds. The goal of pharmaceutical research is to find drugs 
with desirable therapeutic and low risk of undesirable side effects. 
Recent research and development efforts have been channelized 
into the development of drug delivery systems for controlled drug 
administration through various routes (or parts) of administration, 
for example, the skin, to maximize the bioavailability, to optimize 
the therapeutic efficacy, and/or minimize the side effects of the 
drug [1]. 
Transdermal patches offers various advantages over other type of 
conventional dosage forms like improved bioavailability, uniform 
plasma level, reduced dosing interval, user-friendly, avoid first pass 
metabolism and GI irritation, convenient, painless, offering multi-
day dosing, thereby resulting in improved patient compliance [2-4]. 
Schizophrenia is a neuro-developmental psychiatric disorder with 
etiology spanning both genetic and environmental factors. 
According to WHO, schizophrenia affects about 24 million people 
worldwide. It is a treatable disorder, treatment being more effective 
in its initial stages. More than 50% of persons with schizophrenia 
are not receiving appropriate care. 90% of people with untreated 
schizophrenia are in developing countries [5-6]. 
Quetiapine fumerate (QF) is a dibenzothiazepine derivative, an 
atypical antipsychotic with demonstrated efficacy in acute 
schizophrenia. It is indicated for the treatment of schizophrenia as 
well as for the treatment of acute manic episodes associated with 
bipolar I disorder. It has a relatively broad receptor binding profile. 
It has major affinity to cerebral serotonergic (5HT2A), histaminergic 
(H1), and dopaminergic D1 and D2 receptors, moderate affinity to 
đ1- und đ2-adrenergic receptors, and minor affinity to muscarinergic 
M1 receptors; it demonstrates a substantial selectivity for the limbic 
system. It also has an antagonistic effect on the histamine H1 
receptor [7]. 
The aim of present work is to formulate matrix type transdermal 
patches of Quetiapine fumerate using the hydroxypropyl 
methylcellulose (HPMC), and ethylcellulose (EC) to enhance its 
bioavailability and sustain its action. 
Materials and Method 
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Materials 
Quetiapine fumerate was obtained as a gift sample from Aurobindo 
pharmaceuticals, Hyderabad. HPMC was obtained as gift sample 
from Windlass Biotech Ltd., Dehradun. Polyethylene glycol (PEG-
400) was procured from Central Drug House, New Delhi. All other 
chemicals were of analytical grade and were used as provided. 
Method  
Identification by FTIR spectroscopy 
FTIR spectra of drug, and drug-polymer in formulation was carried 
out to find any possible interactions between the drug and the 
polymers during formulation and were obtained in KBr pellets using 
a Perkin Elmer model spectrum BX-FTIR spectrophotometer in the 
ranges, 4000- 400 cm-1. 
Partition coefficient 
The partition coefficient was performed using n-octanol as oil 
phase and phosphate buffer pH 7.4 as aqueous phase. The two 
phases were mixed in equal quantity and 10 mg of weighed 
amount of drug was added. Then, these were saturated on a 
mechanical shaker for 2 hours. The saturated phases were 
separated by separating funnel and equal volume of both phases 
n-octanol and phosphate buffer were taken in a conical flask and 
then analyzed for respective drug controls. The partition coefficient 
of drug Po/w was calculated by the following formula [8]. 
Po/w =  Coil / Cwater (at equilibrium) 
Preparation of drug free polymeric film  
Matrix type transdermal patches were prepared by solvent casting 
technique employing glass and aluminum foil as substrate with few 
modifications [9]. A flat square shaped, aluminum foil coated glass 
mould were fabricated for casting the patches. 
A fixed amount 300 mg of polymers were dissolved in to the 10 ml 
of solvent system (water: methanol, 7:3) using a magnetic stirrer 
for 30 minutes. Then, PEG-400 and DMSO as plasticizer and 
penetration enhancer respectively, were added in the above 
polymeric solution. A weighed quantity of the drug (300mg) was 
dissolved in the polymeric solution. And finally volume makes upto 
20 ml. The solution was poured into the petridish coated by 
aluminum foil and dried at room temperature for 24 h for solvent 
evaporation and an inverted funnel was kept over petridish to 
control the evaporation of solvent. The patches were removed by 
peeling and cut in to squares with dimension of 2x 2 cm2. These 
patches were kept in desiccators for further evaluations. The 
composition of transdermal patches is given in Table 1. 
Evaluation of transdermal films  
Thickness  
The thickness of the film was measured at three different points 
using digital vernier calliper and the average thickness was 
calculated [10]. The experiment was performed in triplicate (n=3). 
Weight uniformity 
For each formulation, three randomly selected patches were used. 
For weight variation test, 3 films from each batch were weighed 
individually and the average weight was calculated [11]. 
Folding endurance 
Folding endurance of the film was determined by repeatedly folding 
a small strip of film (2cm x 2cm) at the same place till it broke. The 
number of times, the film could be folded at the same place without 
breaking, gave the value of folding endurance [12]. 
Percentage moisture content 
The prepared films were weighed individually and kept in a 
desiccator containing fused calcium chloride at room temperature 
for 24 hrs. After 24 hrs the films were reweighed and the 
percentage moisture content was determined by using the given 
formula [13]. 
Percentage moisture content = Initial weight- Final weight  x 100 
           Final weight 
Percentage moisture uptake 
The weighed films were kept in a desiccator at room temperature 
for 24 hrs containing saturated solution of potassium chloride in 
order to maintain 84% RH. After 24 hrs the films were reweighed 
and the percentage moisture uptake was determined by using the 
given formula [14]. 
Percentage moisture uptake = Final weight- Initial weight  x 100 
         Initial weight 
Drug content uniformity 
The uniformity of drug content of the transdermal film was 
determined, based on dry weight of drug and polymer used, by 
means of a UV/VIS spectrophotometer method [15]. A specified 
area (2.5cm2) of patch was cut and dissolved in 5 ml of phosphate 
buffer pH 7.4. Then the solution was transferred in a volumetric 
flask and the volume made up to 10 ml. Appropriate dilutions were 
made using phosphate buffer (pH 7.4), filtered and analyzed for 
drug content at 254 nm by using UV spectrophotometer (Shimadzu 
Pharmspec UV-1700, Japan). (n=3).  
In-vitro drug release 
The in-vitro permeation study of fabricated transdermal patches of 
quetiapine fumerate was carried out by using excised rat 
abdominal skin and franz diffusion cell [9]. The skin was 
sandwiched between donor and receptor compartments of the 
diffusion cell. A 2.2 cm diameter patch was placed in intimate 
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contact with the stratum corneum side of the skin; the top side was 
covered with aluminum foil as a backing membrane. Teflon bead 
was placed in the receptor compartment filled with 12ml of normal 
saline. The cell contents were stirred with a magnetic stirrer and a 
temperature of 32 μ 0.5ĈC was maintained throughout the 
experiment. Samples of 1ml were withdrawn through the sampling 
port at different time intervals for a period of 24h, simultaneously 
replacing equal volume by phosphate buffer (pH 7.4) after each 
withdrawal. Perfect sink conditions were maintained during the 
study. The samples were analyzed spectrophotometrically by UV 
(Shimadzu Pharmspec UV-1700, Japan) at 252nm.  
Statistical analysis 
The results were expressed in mean μ S.D. One way ANOVA 
(Analysis of Variance) was performed for studying the statistical 
significance using Minitab 15 software. Values of P< 0.05 were 
considered to be significant. 
Results and Discussion 
Identification by FTIR spectroscopy 
FTIR spectra of the drug and the formulation predicted that it did 
not show any type of incompatibility. The major peaks of ăCH 
stretching 2948.63, C-N stretching 1575.56, -OH stretching 
3748.68 was also observed in the final formulation (Figure 1-2).  
Partition coefficient 
Partition coefficient of drug in n-octanol/ phosphate buffer pH 7.4 
was found to be 2.7 which indicated that the drug was lipophilic in 
nature. Compounds with values below these optimum values do 
not partition readily into the stratum corneum, while compounds 
with higher values of are so lipophilic that they remain dissolved in 
the stratum corneum [16]. 
Evaluation of transdermal films 
The physicochemical properties (thickness, weight, folding 
endurance, drug content, percentage moisture content and 
percentage moisture uptake) of the transdermal patches are shown 
in Table 2. Thickness of the patches varied between 0.17μ 0.035 to 
0.23μ 0.027 mm. Low standard deviation values in the film 
thickness measurement ensure uniformity of the patches. Weight 
variation of the patches was found to ranging between 193.3μ3.9 
to 203.7μ3.5 mg. Folding endurance was found to be ranging 
between 10μ3.3 to 21μ4.4. Results indicated that as the HPMC 
content decreased, the folding endurance also decreases. Jacob et 
al., 2012 also indicated an increase in polymer concentration 
increases the folding endurance [17]. Folding endurance test result 
indicated that the patches would not break and maintain their 
integrity with general skin folding when applied.  
Drug content (69.62μ0.03 to 86.66μ0.02 mg) of the patches 
indicated the uniformity of the patches. A small standard deviation 
was observed for the drug content. Li et al. (2007) reported that the 
total amount of drug in a transdermal dosage form did not affect 
the magnitude of the drug release but only determines the duration 
of drug delivery [18]. 
Percentage moisture content of  the patches ranged from 
2.19μ0.04% to 4.82μ0.03%.  Maximum % moisture content was 
found in F1 and minimum % moisture content was found in F4 
formulation, respectively. Percentage moisture uptake was found to 
be between 3.40μ0.04% to 4.89μ0.04%. Maximum % moisture 
uptake was found in F5 and minimum % moisture uptake was 
found in F2 formulation, respectively. The results revealed that % 
moisture content and % moisture uptake was found to increase 
with increasing concentration of hydrophilic polymer. The small 
moisture content in formulation helps them to remain stable and 
form a completely dried and brittle film. Again a low moisture 
uptake protects the material from microbial contamination and 
bulkiness of the patches [19]. In most cases, the moisture content 
and uptake was found to increase with increasing concentration of 
hydrophilic polymer [20]. 
In-vitro drug release 
The in vitro drug release pattern of QF from formulated transdermal 
patches is shown in Figure 3. All of these transdermal patches 
slowly released the drug, incorporated and sustained over a period 
of 24 h. The drug release from transdermal patches varied with 
respect to the polymer composition and nature. An increase in drug 
release from the transdermal patches was found with increasing 
concentration of polymers that are more hydrophilic in nature. 
Among all formulations, the maximum in vitro drug release (80.89 
%) over a period of 24 h was observed in the case of formulation 
F2, while the minimum in vitro drug release (58.05 %) over a period 
of 24 h was found in the case of formulation F5. The formulation F1 
with HPMC alone showed drug release of 96.46% in 12 h.  
The drug release was found to increase with increase in the 
concentration of hydrophilic polymer in the polymer matrix. This 
might be due to the fact that dissolution of aqueous soluble fraction  
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Table 1: Composition of transdermal patches 
 
 
 
 
 
 
Table 2: Physical characteristics of transdermal patches 
Parameter  F1 F2 F3 F4 F5 
Thickness(mm)  0.20μ0.03 0.17μ 0.03 0.18μ0.04 0.23μ 0.03 0.21μ0.04
Weight variation  193.3μ3.9 202.7μ3.03 198.7μ3.8 201.4μ2.8 203.7μ3.5
Folding endurance  21.0μ4.4 17.0μ2.5 15.0μ2.3 13.0μ2.9 10.0μ3.3
% Moisture content  4.82μ0.03 3.43μ0.05 3.18μ0.06 2.19μ0.04 2.43μ0.04
%Moisture uptake  4.62μ0.06 3.40μ0.04 4.08μ0.05 4.79μ0.04 4.89μ0.04
Drug content  80.63μ0.02 84.75μ0.03 86.66μ0.02 76.98μ0.04 69.02μ0.03
Values shown are in meanμS.D. (n=3) 
 
 
Figure 1: FTIR spectra of Quetiapine fumerate 
Formulation code Polymers amount (mg) Drug (mg) PEG-400 DMSO
HPMC EC
F1 300 0 300 5% 2% 
F2 200 100 300 5% 2% 
F3 150 150 300 5% 2% 
F4 100 200 300 5% 2% 
F5 0 300 300 5% 2% 
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Figure 2: FTIR spectra of formulation 
 
 
Figure 3: Graph showing drug release from the transdermal patches in phosphate buffer pH 7.4 
 
 
 
of the polymer matrix leads to the formation of pores. The 
formation of such pores leads to decrease in the mean diffusion 
path length of drug molecules to release into the dissolution 
medium and hence to increase the release rate [9]. 
Conclusion 
Quetiapine fumerate patches in combination with HPMC, EC and 
with incorporation of PEG-400 (5%) and DMSO (2%) produced 
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smooth, flexible and transparent film. It can be concluded that 
Quetiapine fumerate produces sustained effect for prolonged 
period by transdermal route for the management of psychosis. 
Transdermal patches of quetiapine fumerate is likely to enhance  
he patient compliance as it would eliminate the need of repeated 
dosing, enhance the bioavalability and sustain the action of the 
drug. 
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